Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Daré Announces Presentation of Two Posters at the 2019 Controlled Release Society Annual Meeting & Exposition
DARE-HRT1 is a potential treatment of menopause-related symptoms DARE-FRT1 is a potential pregnancy maintenance therapy SAN DIEGO , July 22, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that it will be presenting two posters at
View HTML
Toggle Summary Daré Announces Two Late-Breaking Abstracts to be Presented at the American Association of Pharmaceutical Scientists (AAPS) in Washington D.C.
SAN DIEGO , Oct. 30, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it will be presenting two late-breaking abstracts at the upcoming Association of Pharmaceutical Scientists (AAPS) meeting taking place
View HTML
Toggle Summary Daré Bioscience Announces 2019 AAPS Best Abstract Award for Vaginal Tamoxifen for Treatment of Vulvovaginal Atrophy: Pharmacokinetics and Safety in a Rabbit Model
DARE-VVA1 is a proprietary formulation of tamoxifen for vaginal administration as a potential treatment for VVA in patients with hormone receptor-positive breast cancer SAN DIEGO , July 17, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today
View HTML
Toggle Summary Daré Bioscience Announces Appointment of Dr. William H. Rastetter as Chairman of the Board of Directors
SAN DIEGO , July 15, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, announced today that William H. Rastetter , Ph.D., a current member of its Board of Directors, was appointed Chairman of its Board of Directors effective July 11, 2019 .
View HTML
Toggle Summary Daré Bioscience Announces Publication of Pharmacokinetics Study of DARE-HRT1, a Potential Hormone Replacement Therapy, in the Journal of Pharmaceutical Sciences
SAN DIEGO , April 08, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the article entitled “Pharmacokinetics and tolerability of a novel 17β-estradiol and progesterone intravaginal ring in sheep” was published online in the
View HTML
Toggle Summary Daré Bioscience Announces Publication of Positive Clinical Findings for Vaginal Administration of Tamoxifen for the Treatment of VVA
DARE-VVA1 is a proprietary formulation of tamoxifen for vaginal administration as a potential treatment for VVA in patients with hormone-receptor-positive breast cancer SAN DIEGO , March 18, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today
View HTML
Toggle Summary Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-FRT1, a Potential Therapy for Preterm Birth and Fertility, in Drug Delivery and Translational Research
SAN DIEGO, May 8, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the article entitled “Pharmacokinetics and tolerability of a novel progesterone intravaginal ring in sheep” was published online in the journal Drug Delivery and
View HTML
Toggle Summary Daré Bioscience Completes Recruitment in Pre-Pivotal Trial Of Monthly Woman-Controlled, Hormone-Free Contraceptive Candidate, Ovaprene®
Ovaprene has the Potential to be the First FDA-Approved Monthly, Self-Administered, Hormone-Free Contraceptive SAN DIEGO, Calif. , June 26, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced completion of patient recruitment in its
View HTML
Toggle Summary Daré Bioscience Provides Business Update and Announces Third Quarter Financial Results
SAN DIEGO , Nov. 13, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today provided a business update and announced financial results for the three and nine months ended September 30, 2018.
View HTML
Toggle Summary Daré Bioscience Provides Update for Investors on Development Programs and Anticipated 2019 Milestones
Key anticipated 2019 clinical milestones: Topline results of Ovaprene® PCT clinical trial Initiation of at-home portion of Sildenafil Cream, 3.6% Phase 2b Initiation of pivotal Phase 3 study of DARE-BV1 SAN DIEGO , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.
View HTML